Chronic liver injury, TGF-β, and cancer

[1]  K. Nouso,et al.  Telomere length in human liver diseases. , 2008, Liver.

[2]  S. Terai,et al.  Herbal medicine Inchin-ko-to (TJ-135) prevents liver fibrosis and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. , 2003, Journal of hepatology.

[3]  Hyung-Lae Kim,et al.  Cleavage of purified neuronal clathrin assembly protein (CALM) by caspase 3 and calpain , 2001, Experimental & Molecular Medicine.

[4]  S. Galadari,et al.  Effects of cations on ceramide-activated protein phosphatase 2A , 2001, Experimental & Molecular Medicine.

[5]  H. Yoshiji,et al.  Angiotensin‐II type 1 receptor interaction is a major regulator for liver fibrosis development in rats , 2001, Hepatology.

[6]  T. Macdonald,et al.  Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. , 2001, The Journal of clinical investigation.

[7]  J D Malley,et al.  Studies of murine schistosomiasis reveal interleukin‐13 blockade as a treatment for established and progressive liver fibrosis , 2001, Hepatology.

[8]  N. Terrault,et al.  Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: A comparative study using a matched, untreated cohort , 2001, Hepatology.

[9]  Y Ando,et al.  Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. , 2001, Gastroenterology.

[10]  L. Ferrell,et al.  Activation of the Met Receptor by Cell Attachment Induces and Sustains Hepatocellular Carcinomas in Transgenic Mice , 2001, The Journal of cell biology.

[11]  J. Stephenson.  Studies illuminate cause of fatal reaction in gene-therapy trial. , 2001, JAMA.

[12]  T. Davern.  Molecular therapeutics of liver disease. , 2001, Clinics in liver disease.

[13]  M. Yáñez-Mó,et al.  The hepatitis B virus X protein (HBx) induces a migratory phenotype in a CD44‐dependent manner: Possible role of HBx in invasion and metastasis , 2001, Hepatology.

[14]  T. Pihlajaniemi,et al.  Tumor hepatocytes and basement membrane–Producing cells specifically express two different forms of the endostatin precursor, collagen XVIII, in human liver cancers , 2001, Hepatology.

[15]  M. Serio,et al.  Signal Transduction by the Chemokine Receptor CXCR3 , 2001, The Journal of Biological Chemistry.

[16]  R. Schulte‐Hermann,et al.  Biology of transforming growth factor β in hepatocarcinogenesis , 2001, Microscopy research and technique.

[17]  A. Nagler,et al.  Halofuginone to prevent and treat thioacetamide‐induced liver fibrosis in rats , 2001, Hepatology.

[18]  P. Tangkijvanich,et al.  Wound‐induced migration of rat hepatic stellate cells is modulated by endothelin‐1 through rho‐kinase‐mediated alterations in the acto‐myosin cytoskeleton , 2001, Hepatology.

[19]  T. Roskams,et al.  Human and rat hepatic stellate cells express neurotrophins and neurotrophin receptors , 2001, Hepatology.

[20]  N. Kawada,et al.  Inhibition of hepatic stellate cell proliferation and activation by the semisynthetic analogue of fumagillin TNP‐470 in rats , 2000, Hepatology.

[21]  G. Davis,et al.  Impact of interferon alfa‐2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C , 2000, Hepatology.

[22]  T. Therneau,et al.  Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid , 2000, Hepatology.

[23]  Ester Piek,et al.  Role of Transforming Growth Factor-β Signaling in Cancer , 2000 .

[24]  A. Gentilini,et al.  Nitrovasodilators inhibit platelet-derived growth factor-induced proliferation and migration of activated human hepatic stellate cells. , 2000, Gastroenterology.

[25]  T. Ueno,et al.  Inhibition of transforming growth factor β prevents progression of liver fibrosis and enhances hepatocyte regeneration in dimethylnitrosamine‐treated rats , 2000, Hepatology.

[26]  D. Schuppan,et al.  An oral endothelin-A receptor antagonist blocks collagen synthesis and deposition in advanced rat liver fibrosis. , 2000, Gastroenterology.

[27]  S. Dooley,et al.  Modulation of transforming growth factor β response and signaling during transdifferentiation of rat hepatic stellate cells to myofibroblasts , 2000, Hepatology.

[28]  R. Hultcrantz,et al.  PDGF-Mediated Chemoattraction of Hepatic Stellate Cells by Bile Duct Segments in Cholestatic Liver Injury , 2000, Laboratory Investigation.

[29]  D. Schuppan,et al.  Successful Targeting to Rat Hepatic Stellate Cells Using Albumin Modified with Cyclic Peptides That Recognize the Collagen Type VI Receptor* , 2000, The Journal of Biological Chemistry.

[30]  M. Sata,et al.  Histologic Improvement of Fibrosis in Patients with Hepatitis C Who Have Sustained Response to Interferon Therapy , 2000, Annals of Internal Medicine.

[31]  G. Davis,et al.  Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. , 2000, Gastroenterology.

[32]  D. Purdie,et al.  Host genetic factors influence disease progression in chronic hepatitis C , 2000, Hepatology.

[33]  J. Massagué,et al.  Controlling TGF-β signaling , 2000, Genes & Development.

[34]  K. Matsuzaki,et al.  Autocrine stimulatory mechanism by transforming growth factor beta in human hepatocellular carcinoma. , 2000, Cancer research.

[35]  R. DePinho,et al.  Inhibition of experimental liver cirrhosis in mice by telomerase gene delivery. , 2000, Science.

[36]  S. Friedman.  Molecular Regulation of Hepatic Fibrosis, an Integrated Cellular Response to Tissue Injury* , 2000, The Journal of Biological Chemistry.

[37]  J. Villeneuve,et al.  Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B , 2000, Hepatology.

[38]  S. Thorgeirsson,et al.  Chemical hepatocarcinogenesis in transgenic mice overexpressing mature TGF beta-1 in liver. , 1999, European journal of cancer.

[39]  R. Timpl,et al.  Localization of liver myofibroblasts and hepatic stellate cells in normal and diseased rat livers: distinct roles of (myo-)fibroblast subpopulations in hepatic tissue repair , 1999, Histochemistry and Cell Biology.

[40]  M. Kaplan,et al.  A prospective trial of colchicine and methotrexate in the treatment of primary biliary cirrhosis. , 1999, Gastroenterology.

[41]  V. Koteliansky,et al.  In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[42]  T. Wynn,et al.  An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response. , 1999, The Journal of clinical investigation.

[43]  K. Yoshioka,et al.  Gene mutation of transforming growth factor β1 type II receptor in hepatocellular carcinoma , 1999, International journal of cancer.

[44]  O. Weiland,et al.  Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon. , 1999, Journal of hepatology.

[45]  P. Olinga,et al.  Albumin modified with mannose 6‐phosphate: A potential carrier for selective delivery of antifibrotic drugs to rat and human hepatic stellate cells , 1999, Hepatology.

[46]  A. Desmoulière,et al.  Effect of pentoxifylline on early proliferation and phenotypic modulation of fibrogenic cells in two rat models of liver fibrosis and on cultured hepatic stellate cells. , 1999, Journal of hepatology.

[47]  A. Ooshima,et al.  Blockade of type beta transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[48]  H. Friess,et al.  Transforming growth factor betas and their signaling receptors in human hepatocellular carcinoma. , 1999, American journal of surgery.

[49]  C. Gandhi,et al.  Down-regulation of endothelin receptors by transforming growth factor beta1 in hepatic stellate cells. , 1999, Journal of hepatology.

[50]  D. Schuppan,et al.  A histone deacetylase inhibitor, trichostatin A, suppresses myofibroblastic differentiation of rat hepatic stellate cells in primary culture , 1999, Hepatology.

[51]  Y. Kaneda,et al.  Hepatocyte growth factor gene therapy of liver cirrhosis in rats , 1999, Nature Medicine.

[52]  T. Niki,et al.  Class VI intermediate filament protein nestin is induced during activation of rat hepatic stellate cells , 1999, Hepatology.

[53]  Fei Liu,et al.  Effects of sho‐saiko‐to, a japanese herbal medicine, on hepatic fibrosis in rats , 1999, Hepatology.

[54]  F. Marra,et al.  Monocyte chemotactic protein‐1 as a chemoattractant for human hepatic stellate cells , 1999, Hepatology.

[55]  Wei Wu,et al.  Interleukin‐10 controls neutrophilic infiltration, hepatocyte proliferation, and liver fibrosis induced by carbon tetrachloride in mice , 1998, Hepatology.

[56]  J. Fallowfield,et al.  Interleukin‐10 expression and function in experimental murine liver inflammation and fibrosis , 1998, Hepatology.

[57]  K. Okita,et al.  Inhibitory effects of the herbal medicine Sho-saiko-to (TJ-9) on cell proliferation and procollagen gene expressions in cultured rat hepatic stellate cells. , 1998, Journal of hepatology.

[58]  J. Graff,et al.  Smad3 Mutant Mice Develop Metastatic Colorectal Cancer , 1998, Cell.

[59]  B. Ruttkay-Nedecky,et al.  Levels of transforming growth factor β and transforming growth factor β receptors in rat liver during growth, regression by apoptosis and neoplasia , 1998 .

[60]  J. Iredale,et al.  Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. , 1998, The Journal of clinical investigation.

[61]  S. Friedman,et al.  Coordinated induction of VEGF receptors in mesenchymal cell types during rat hepatic wound healing , 1998, Oncogene.

[62]  D. Stolz,et al.  Differential modulation of hepatocyte growth factor‐stimulated motility by transforming growth factor β1 on rat liver epithelial cells in vitro , 1998, Journal of cellular physiology.

[63]  J. Panés,et al.  Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. , 1998, Journal of hepatology.

[64]  Anita B. Roberts,et al.  REGULATION OF IMMUNE RESPONSES BY TGF-β* , 1998 .

[65]  N. Kawada,et al.  Endothelin‐1–induced vasoconstriction causes a significant increase in portal pressure of rat liver: Localized constrictive effect on the distal segment of preterminal portal venules as revealed by light and electron microscopy and serial reconstruction , 1998, Hepatology.

[66]  R. Rippe,et al.  Expression of Interleukin-10 by in Vitro and in Vivo Activated Hepatic Stellate Cells* , 1998, The Journal of Biological Chemistry.

[67]  D. Stolz,et al.  Extracellular matrix remodeling at the early stages of liver regeneration in the rat , 1997, Hepatology.

[68]  D. Schuppan,et al.  Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats , 1997, Hepatology.

[69]  A. Nagler,et al.  Halofuginone, a specific inhibitor of collagen type I synthesis, prevents dimethylnitrosamine-induced liver cirrhosis. , 1997, Journal of hepatology.

[70]  A. Mallat,et al.  Pentoxifylline inhibits growth and collagen synthesis of cultured human hepatic myofibroblast‐like cells , 1997, Hepatology.

[71]  K. Matsumoto,et al.  Preventive and therapeutic effects in rats of hepatocyte growth factor infusion on liver fibrosis/cirrhosis , 1997, Hepatology.

[72]  Teruaki Kimura,et al.  Prolyl 4-hydroxylase inhibitor (HOE 077) inhibits pig serum-induced rat liver fibrosis by preventing stellate cell activation. , 1997, Journal of hepatology.

[73]  S. Thorgeirsson,et al.  Constitutive expression of mature transforming growth factor beta1 in the liver accelerates hepatocarcinogenesis in transgenic mice. , 1997, Cancer research.

[74]  P. Bedossa,et al.  Natural history of liver fibrosis progression in patients with chronic hepatitis C , 1997, The Lancet.

[75]  E. Engvall,et al.  Integrins and vascular extracellular matrix assembly. , 1997, The Journal of clinical investigation.

[76]  M. Foschi,et al.  Neutrophil‐derived superoxide anion induces lipid peroxidation and stimulates collagen synthesis in human hepatic stellate cells: Role of nitric oxide , 1997, Hepatology.

[77]  R. Sharp,et al.  Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[78]  A. Gentilini,et al.  Inhibition by pentoxifylline of extracellular signal‐regulated kinase activation by platelet‐derived growth factor in hepatic stellate cells , 1996, British journal of pharmacology.

[79]  R. Hynes,et al.  Mesodermal development in mouse embryos mutant for fibronectin , 1996, Developmental dynamics : an official publication of the American Association of Anatomists.

[80]  F. Lithner,et al.  The epidemiology of hepatocellular carcinoma in patients with acute intermittent porphyria , 1996, Journal of internal medicine.

[81]  D. Rockey,et al.  Endothelin antagonism in experimental hepatic fibrosis. Implications for endothelin in the pathogenesis of wound healing. , 1996, The Journal of clinical investigation.

[82]  E. Imai,et al.  Antifibrogenic effect of a deletion variant of hepatocyte growth factor on liver fibrosis in rats , 1996, Hepatology.

[83]  J. Iredale,et al.  Tissue inhibitor of metalloproteinase‐1 messenger RNA expression is enhanced relative to interstitial collagenase messenger RNA in experimental liver injury and fibrosis , 1996, Hepatology.

[84]  D. Demetrick,et al.  Mutation analysis of the transforming growth factor beta type II receptor in sporadic human cancers of the pancreas, liver, and breast. , 1996, Biochemical and biophysical research communications.

[85]  G. Ramadori,et al.  Glial fibrillary acidic protein--a cell type specific marker for Ito cells in vivo and in vitro. , 1996, Journal of hepatology.

[86]  R. Gebhardt,et al.  Colocalization of three types of intermediate filament proteins in perisinusoidal stellate cells: glial fibrillary acidic protein as a new cellular marker. , 1996, European journal of cell biology.

[87]  Gressner Am.  Transdifferentiation of hepatic stellate cells (Ito cells) to myofibroblasts: a key event in hepatic fibrogenesis. , 1996 .

[88]  K. Okita,et al.  The prolyl 4‐hydroxylase inhibitor HOE 077 prevents activation of Ito cells, reducing procollagen gene expression in rat liver fibrosis induced by choline‐deficient L‐amino acid‐defined diet , 1996, Hepatology.

[89]  D. Häussinger,et al.  Long-term survival in patients with hereditary hemochromatosis. , 1996, Gastroenterology.

[90]  T. C. Peterson,et al.  Effect of pentoxifylline in rat and swine models of hepatic fibrosis: role of fibroproliferation in its mechanism. , 1996, Immunopharmacology.

[91]  S. Milani,et al.  Endothelin 1 is overexpressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells. , 1996, Gastroenterology.

[92]  A. Gentilini,et al.  The mitogenic effect of platelet-derived growth factor in human hepatic stellate cells requires calcium influx. , 1995, The American journal of physiology.

[93]  K. Matsumoto,et al.  Hepatocyte growth factor suppresses the onset of liver cirrhosis and abrogates lethal hepatic dysfunction in rats. , 1995, Journal of biochemistry.

[94]  A. Sher,et al.  An IL-12-based vaccination method for preventing fibrosis induced by schistosome infection , 1995, Nature.

[95]  D M Bissell,et al.  Cell-specific expression of transforming growth factor-beta in rat liver. Evidence for autocrine regulation of hepatocyte proliferation. , 1995, The Journal of clinical investigation.

[96]  D. Rockey,et al.  Expression of variant fibronectins in wound healing: cellular source and biological activity of the EIIIA segment in rat hepatic fibrogenesis , 1994, The Journal of cell biology.

[97]  M. Clemens,et al.  Endothelin-1 induces direct constriction of hepatic sinusoids. , 1994, The American journal of physiology.

[98]  D. Schuppan,et al.  Ito cell heterogeneity: Desmin‐negative ito cells in normal rat liver , 1994, Hepatology.

[99]  K. Yamamura,et al.  Chronic active hepatitis in transgenic mice expressing interferon-gamma in the liver. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[100]  D. Rockey,et al.  Endothelin receptors in rat liver: lipocytes as a contractile target for endothelin 1. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[101]  S. Friedman,et al.  Activation-dependent contractility of rat hepatic lipocytes in culture and in vivo. , 1993, The Journal of clinical investigation.

[102]  S. Friedman.  The Cellular Basis of Hepatic Fibrosis -- Mechanisms and Treatment Strategies , 1993 .

[103]  S. Friedman,et al.  Retinol release by activated rat hepatic lipocytes: regulation by Kupffer cell-conditioned medium and PDGF. , 1993, The American journal of physiology.

[104]  T. C. Peterson.  Pentoxifylline prevents fibrosis in an animal model and inhibits platelet‐derived growth factor–driven proliferation of fibroblasts , 1993, Hepatology.

[105]  G. Proetzel,et al.  Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease , 1992, Nature.

[106]  G. Poli,et al.  Vitamin E dietary supplementation protects against carbon tetrachloride—induced chronic liver damage and cirrhosis , 1992, Hepatology.

[107]  M. Odenthal,et al.  Synthesis of cellular fibronectin by rat liver fat-storing (Ito) cells: regulation by cytokines. , 1992, Gastroenterology.

[108]  N. Kawada,et al.  Eicosanoid-mediated contractility of hepatic stellate cells. , 1992, The Biochemical journal.

[109]  R. F. McGuire,et al.  Role of extracellular matrix in regulating fenestrations of sinusoidal endothelial cells isolated from normal rat liver , 1992, Hepatology.

[110]  M. Sporn,et al.  Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1 , 1990, Nature.

[111]  S. Friedman,et al.  Activation of cultured rat hepatic lipocytes by Kupffer cell conditioned medium. Direct enhancement of matrix synthesis and stimulation of cell proliferation via induction of platelet-derived growth factor receptors. , 1989, The Journal of clinical investigation.

[112]  S. Friedman,et al.  Lipocytes from normal rat liver release a neutral metalloproteinase that degrades basement membrane (type IV) collagen. , 1989, The Journal of clinical investigation.

[113]  Harold E. Dvorak,et al.  Reappearance of an embryonic pattern of fibronectin splicing during wound healing in the adult rat , 1989, The Journal of cell biology.

[114]  B. Schneider,et al.  Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. , 1989, Journal of hepatology.

[115]  L. Ala‐Kokko,et al.  Preventive effect of malotilate on dimethylnitrosamine-induced liver fibrosis in the rat. , 1989, The Journal of laboratory and clinical medicine.

[116]  R. Coffey,et al.  Type beta transforming growth factor reversibly inhibits the early proliferative response to partial hepatectomy in the rat. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[117]  F. Schaffner,et al.  Evaluation of colchicine therapy in primary biliary cirrhosis. , 1988, Gastroenterology.

[118]  M. Gent,et al.  Colchicine in the treatment of cirrhosis of the liver. , 1988, The New England journal of medicine.

[119]  J. Bloomer.  The liver in protoporphyria , 1988, Hepatology.

[120]  M. Kaplan,et al.  A prospective trial of colchicine for primary biliary cirrhosis. , 1986, The New England journal of medicine.

[121]  S. Friedman,et al.  Hepatic lipocytes: the principal collagen-producing cells of normal rat liver. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[122]  C. Vater,et al.  Native cross-links in collagen fibrils induce resistance to human synovial collagenase. , 1979, The Biochemical journal.

[123]  H. Popper,et al.  Vitamin A-containing lipocytes and formation of type III collagen in liver injury. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[124]  H. Popper,et al.  Capillarization of hepatic sinusoids in man. , 1963, Gastroenterology.

[125]  T. Nakamura,et al.  A soluble transforming growth factor beta receptor expressed in muscle prevents liver fibrogenesis and dysfunction in rats. , 2000, Human gene therapy.

[126]  J. Massagué,et al.  Controlling TGF-beta signaling. , 2000, Genes & development.

[127]  H. Kuwano,et al.  Mutation analysis of transforming growth factor beta type II receptor, Smad2, and Smad4 in hepatocellular carcinoma. , 1999, International journal of oncology.

[128]  T. Kuroki,et al.  Quantitative analysis and in situ localization of human telomerase RNA in chronic liver disease and hepatocellular carcinoma. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[129]  V. Guenzler,et al.  Two novel antifibrotics, HOE 077 and Safironil, modulate stellate cell activation in rat liver injury: differential effects in males and females. , 1998, The American journal of pathology.

[130]  A. Roberts,et al.  Regulation of immune responses by TGF-beta. , 1998, Annual review of immunology.

[131]  K. Okita,et al.  Herbal medicine Sho-saiko-to (TJ-9) prevents liver fibrosis and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. , 1998, Journal of hepatology.

[132]  B. Ruttkay-Nedecky,et al.  Levels of transforming growth factor beta and transforming growth factor beta receptors in rat liver during growth, regression by apoptosis and neoplasia. , 1998, Hepatology.

[133]  J. Iredale.  Tissue inhibitors of metalloproteinases in liver fibrosis. , 1997, The international journal of biochemistry & cell biology.

[134]  A. Gressner.  Transdifferentiation of hepatic stellate cells (Ito cells) to myofibroblasts: a key event in hepatic fibrogenesis. , 1996, Kidney international. Supplement.

[135]  M. Arthur.  Collagenases and liver fibrosis. , 1995, Journal of hepatology.

[136]  B. Westermark,et al.  Transforming growth factor-beta promotes epidermal growth factor-induced thyroid cell migration and follicle neoformation in collagen gel separable from cell proliferation. , 1995, Experimental Cell Research.

[137]  B. Kommerell,et al.  Hepatocyte proliferation in primary biliary cirrhosis as assessed by proliferating cell nuclear antigen and Ki-67 antigen labelling. , 1995, Journal of hepatology.

[138]  S. D. Lee,et al.  A double-blind randomized controlled trial of colchicine in patients with hepatitis B virus-related postnecrotic cirrhosis. , 1994, Journal of hepatology.

[139]  N. Keiding,et al.  The prognosis of patients with alcoholic liver disease. An international randomized, placebo-controlled trial on the effect of malotilate on survival. , 1994, Journal of hepatology.

[140]  The results of a randomized double blind controlled trial evaluating malotilate in primary biliary cirrhosis. A European multicentre study group. , 1993, Journal of hepatology.

[141]  A. Gressner,et al.  Activation of rat liver perisinusoidal lipocytes by transforming growth factors derived from myofibroblastlike cells. A potential mechanism of self perpetuation in liver fibrogenesis. , 1992, The Journal of clinical investigation.

[142]  J. Saric,et al.  Nerves and perisinusoidal cells in human liver. , 1990, Journal of hepatology.

[143]  D. Bissell.  Cell-matrix interaction and hepatic fibrosis. , 1990, Progress in liver diseases.

[144]  Bissell Dm.  Cell-matrix interaction and hepatic fibrosis. , 1990 .

[145]  D. Bissell,et al.  The role of extracellular matrix in normal liver. , 1988, Scandinavian journal of gastroenterology. Supplement.